Arcellx Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $34.42
- Today's High:
- $35.95
- Open Price:
- $35.41
- 52W Low:
- $6.035
- 52W High:
- $35.26
- Prev. Close:
- $35.69
- Volume:
- 485742
Company Statistics
- Market Cap.:
- $1.31 billion
- Book Value:
- 5.389
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -44.57%
- Return on Equity TTM:
- -93.13%
Company Profile
Arcellx Inc had its IPO on 2022-02-04 under the ticker symbol ACLX.
The company operates in the Healthcare sector and Biotechnology industry. Arcellx Inc has a staff strength of 78 employees.
Stock update
Shares of Arcellx Inc opened at $35.41 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $34.42 - $35.95, and closed at $34.5.
This is a -3.33% slip from the previous day's closing price.
A total volume of 485,742 shares were traded at the close of the day’s session.
In the last one week, shares of Arcellx Inc have slipped by -7.75%.
Arcellx Inc's Key Ratios
Arcellx Inc has a market cap of $1.31 billion, indicating a price to book ratio of 6.1247 and a price to sales ratio of 0.
In the last 12-months Arcellx Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-170718000. The EBITDA ratio measures Arcellx Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Arcellx Inc’s operating margin was 0% while its return on assets stood at -44.57% with a return of equity of -93.13%.
In Q3, Arcellx Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Arcellx Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-3.91 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Arcellx Inc’s profitability.
Arcellx Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -7.3412. Its price to sales ratio in the trailing 12-months stood at 0.
Arcellx Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $337.33 million
- Total Liabilities
- $44.78 million
- Operating Cash Flow
- $-81420000.00
- Capital Expenditure
- $385000
- Dividend Payout Ratio
- 0%
Arcellx Inc ended 2024 with $337.33 million in total assets and $0 in total liabilities. Its intangible assets were valued at $337.33 million while shareholder equity stood at $236.28 million.
Arcellx Inc ended 2024 with $5.52 million in deferred long-term liabilities, $44.78 million in other current liabilities, 44000.00 in common stock, $-279798000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $56.76 million and cash and short-term investments were $280.78 million. The company’s total short-term debt was $30,603,000 while long-term debt stood at $0.
Arcellx Inc’s total current assets stands at $290.31 million while long-term investments were $0 and short-term investments were $224.02 million. Its net receivables were $0 compared to accounts payable of $2.96 million and inventory worth $0.
In 2024, Arcellx Inc's operating cash flow was $-81420000.00 while its capital expenditure stood at $385000.
Comparatively, Arcellx Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $34.5
- 52-Week High
- $35.26
- 52-Week Low
- $6.035
- Analyst Target Price
- $38
Arcellx Inc stock is currently trading at $34.5 per share. It touched a 52-week high of $35.26 and a 52-week low of $35.26. Analysts tracking the stock have a 12-month average target price of $38.
Its 50-day moving average was $34.44 and 200-day moving average was $33.29 The short ratio stood at 8.16 indicating a short percent outstanding of 0%.
Around 1684.1% of the company’s stock are held by insiders while 10087.5% are held by institutions.
Frequently Asked Questions About Arcellx Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company’s lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. It has strategic alliance with Kite to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.